Effectiveness of Cabergoline in prevention of Ovarian hyperstimulation syndrome in hyperprolactinaemic patients with polycystic ovary syndrome

Abstract

polycystic ovary syndrome (PCOS) associated with abnormal secretion of gonadotrophin,  (high concentration of LH serum, depressed FSH level, also an LH/FSH ratio≥2).Hyperprolactinaemia is generally PCOS-associated (about 30 percent of female).Viewed also in both normal and stimulated cycles,throughout the late phases of follicular and luteal. It is proposed that both prolactin (PRL) and LH may be increased bya drop in the inhibitory dopamine effect.The aim of the study is to evaluate the effect of cabergoline on fertility parameters in females with controlled ovarian stimulation of PCOS. Patients and method: Ovarian stimulation was compared between two groups of females with hyperprolactinaemic-PCOS; cabergoline was given to the first group, decreasing plasma PRL concentrations that typically seen with the induction of ovulation. This paper found out a decreased total number of FSH recombinants (P<0.04) was observed, ampoulesin the untreated group of hyperprolactinaemiPCOS. Fewer days for HCG administration to meet (P < 0.044), A significantly higher peak plasma concentration of oestrogen (P < 0.03) in comparison with the group that were treated. This group demonstrated substantially greater ovarian volume and improved total follicle numbers of all sizes by ultrasound inspection.Due to a mild syndrome of ovarian hyperstimulation that occurred during induction of ovulation, five cycles of 58 were cancelled regarding untreated hyperPRL-PCOS females. two out of 42 cycles was cancelled in patients treated with cabergoline. No major variations were found in the pregnancy rate or multiple pregnancies.In generalthe data indicate dopaminergic regulation of release of LH and encourage cabergoline usage in these patients' treatment, To maintain better monitoring of the response of the ovaries and, therefore, To reduce the OHSS, without reducingpregnancy chances